⌘K
Loading ticker…
As of 2026-08-24, Moderna, Inc. Common Stock (MRNA) has a 3-month relative strength percentile of 99 and a leadership percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 98. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 10.3%, relative volume 1.33×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MRNA is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 100.2% / 181.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
MRNA is held by 59 ETFs as of May 2026. Top owner: CGGR at 0.39% weight, $95M notional. Top 3 carry $183M.
Held by 185 ETFs · $3.6B across latest filings · largest weight 6.28% (IDNA).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| CGGR | 0.39% | $95M | −0.08 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.30% | $44M | −0.07 pp |
| VHTVanguard Health Care ETF | 0.23% | $43M | −0.01 pp |
| FNDXSchwab Fundamental U.S. Large Company Index ETF | 0.15% | $39M | −0.04 pp |
| SCHG |
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.06% |
| $35M |
| −0.01 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $18M | — |
| VONVVanguard Russell 1000 Value ETF | 0.05% | $11M | — |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $10M | — |
| SPHBInvesco S&P 500 High Beta ETF | 0.93% | $10M | −0.17 pp |
| ESML | 0.28% | $7M | −0.05 pp |
Showing 10 of 59 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MRNA Jan avg: 10.97% median: -0.19% win: 50% σ: 25.80% n: 4 2022-04-12 → 2026-07-31 | MRNA Feb avg: -7.45% median: -14.94% win: 25% σ: 20.23% n: 4 2022-04-12 → 2026-07-31 | MRNA Mar avg: 3.14% median: 2.73% win: 50% σ: 11.73% n: 4 2022-04-12 → 2026-07-31 | MRNA Apr avg: -6.97% median: -9.57% win: 40% σ: 8.64% n: 5 2022-04-12 → 2026-07-31 | MRNA May avg: 5.85% median: 2.72% win: 60% σ: 14.32% n: 5 2022-04-12 → 2026-07-31 | MRNA Jun avg: 5.80% median: -1.71% win: 40% σ: 24.97% n: 5 2022-04-12 → 2026-07-31 | MRNA Jul avg: -0.50% median: 0.40% win: 60% σ: 13.72% n: 5 2022-04-12 → 2026-07-31 | MRNA Aug avg: -19.22% median: -18.95% win: 0% σ: 12.74% n: 4 2022-04-12 → 2026-07-31 (current) | MRNA Sep avg: -6.42% median: -9.63% win: 25% σ: 9.33% n: 4 2022-04-12 → 2026-07-31 | MRNA Oct avg: -3.21% median: -6.75% win: 50% σ: 24.29% n: 4 2022-04-12 → 2026-07-31 | MRNA Nov avg: -1.46% median: -1.03% win: 50% σ: 15.68% n: 4 2022-04-12 → 2026-07-31 | MRNA Dec avg: 10.04% median: 7.81% win: 75% σ: 13.89% n: 4 2022-04-12 → 2026-07-31 |